During the recent session, SELLAS Life Sciences Group Inc (NASDAQ:SLS)’s traded shares were 0.82 million, with the beta value of the company hitting 2.41. At the last check today, the stock’s price was $1.05, reflecting an intraday gain of 1.44% or $0.01. The 52-week high for the SLS share is $1.72, that puts it down -63.81 from that peak though still a striking 52.38% gain since the share price plummeted to a 52-week low of $0.50. The company’s market capitalization is $74.26M, and the average intraday trading volume over the past 10 days was 1.05 million shares, and the average trade volume was 1.02 million shares over the past three months.
SELLAS Life Sciences Group Inc (SLS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. SLS has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SELLAS Life Sciences Group Inc (NASDAQ:SLS) trade information
SELLAS Life Sciences Group Inc (SLS) registered a 1.44% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.44% in intraday trading to $1.05, hitting a weekly high. The stock’s 5-day price performance is 13.50%, and it has moved by -9.05% in 30 days. Based on these gigs, the overall price performance for the year is 17.22%. The short interest in SELLAS Life Sciences Group Inc (NASDAQ:SLS) is 8.61 million shares and it means that shorts have 14.07 day(s) to cover.
The consensus price target of analysts on Wall Street is $2.8, which implies an increase of 62.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.4 and $3.2 respectively. As a result, SLS is trading at a discount of -204.76% off the target high and -128.57% off the low.
SELLAS Life Sciences Group Inc (SLS) estimates and forecasts
Statistics show that SELLAS Life Sciences Group Inc has outperformed its competitors in share price, compared to the industry in which it operates. SELLAS Life Sciences Group Inc (SLS) shares have gone down -7.46% during the last six months, with a year-to-date growth rate more than the industry average at 57.46% against 16.70.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 61.44%. While earnings are projected to return 59.95% in 2025.
SLS Dividends
SELLAS Life Sciences Group Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
SELLAS Life Sciences Group Inc (NASDAQ:SLS)’s Major holders
SELLAS Life Sciences Group Inc insiders own 0.24% of total outstanding shares while institutional holders control 7.36%, with the float percentage being 7.38%. VANGUARD GROUP INC is the largest shareholder of the company, while 35.0 institutions own stock in it. As of 2024-06-30, the company held over 1.79 million shares (or 3.9862% of all shares), a total value of $2.13 million in shares.
The next largest institutional holding, with 1.64 million shares, is of SUSQUEHANNA INTERNATIONAL GROUP, LLP’s that is approximately 3.6594% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.95 million.
